Neogenomics Inc (NEO) · Oct 28, 2026 · Earnings

NeoGenomics earnings beat as FY26 revenue and EBITDA guidance rise

Beat — Adjusted diluted EPS $0.07 vs ~$0.06 consensus; revenue $209.3M vs ~$206.7M consensus

NeoGenomics earnings beat Q3 revenue and adjusted EPS expectations, while FY26 revenue and EBITDA guidance moved higher.

NeoGenomics is shifting toward higher-value oncology testing—especially next-generation sequencing and molecular residual disease assays—while trying to improve margins through payer expansion, digital infrastructure, and operating efficiency. That strategy is showing up in the mix: the company’s own 2026 priorities emphasize NGS, RaDaR ST, community oncology expansion, and scalable operations.

The quarter cleared published expectations, but not by a wide margin. Revenue was $209.3 million versus consensus of approximately $206.7 million, while adjusted diluted EPS was $0.07 versus roughly $0.06 expected. Revenue growth was supported more by pricing and mix than by volume: clinical test volume rose 2%, while average revenue per test increased 11% to $530.

MetricQ3 2026Q3 2025Comparison / expectation
Revenue$209.3M$187.8M+11.4%; vs ~$206.7M consensus
GAAP net loss$(7.5)M$(27.1)MLoss narrowed 72%
Adjusted EBITDA$18.7M$12.2M+53%
Adjusted diluted EPS$0.07$0.03vs ~$0.06 consensus
Clinical test volume367,279360,774+1.8%
Average revenue per test$530$476+11.3%

The more important improvement is operating leverage. Gross margin expanded to 46.2% from 42.8%, and adjusted EBITDA rose 53% to $18.7 million despite only 11% revenue growth. The business is therefore progressing toward its stated goal of growing faster through higher-value tests rather than simply processing more samples.

Full-year guidance moved up, although the surprise was partly disclosed already. Revenue guidance increased from $802–806 million to $807–809 million, and adjusted EBITDA guidance rose from $56–58 million to approximately $60 million. The revenue range had been effectively previewed by the company’s October 5 preliminary update, so the new information is mainly the confirmed quarterly beat and the modestly better profitability outlook.

Cash generation remains the constraint behind the improvement story. NeoGenomics produced only $2.9 million of operating cash flow in the first nine months while spending $25.0 million on property and equipment, and cash declined to $139.3 million from $159.6 million at year-end. The earnings improvement is real, but it has not yet translated into substantial free cash generation.

Bottom line: This was a genuine earnings beat with better margins and a modest guidance lift, strengthening the case that NeoGenomics’ NGS-led mix shift is working. The signal is positive, but the revenue upside was partly known and cash conversion is still unfinished business.

What to watch next

CEO succession effective January 4, 2027

Original filing on SEC EDGAR

More Neogenomics Inc news

NeoGenomics earnings beat as FY26 revenue and EBITDA guidance rise | NEO Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.